Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Piffer OT - And Other Assorted Nuts -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (8695)	12/1/1999 11:56:00 AM
From: wlheatmoon	Read Replies (1) \| Respond to of 63513

NMPS woke up a bit today with patent news...-g- Wednesday December 1, 8:59 am Eastern Time Company Press Release SOURCE: Matritech, Inc. Matritech Issued Patent Extending U.S. Coverage of Its Fluid-Based Nuclear Matrix Protein Cancer Detection Technology Until 2011 NEWTON, Mass., Dec. 1 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS - news), a company specializing in products designed to detect, manage and screen cancer, announced today that it has been awarded U.S. Patent No. 5,989,826 for its proprietary fluid-based nuclear matrix protein (NMP) technology to detect cancer in body fluid samples including blood, urine, spinal fluid and sputum. The patent provides protection in the United States until 2011 for all of Matritech's fluid-based assays currently being sold or under development, including the NMP22© Bladder Cancer Test Kit, the NuMA(TM) Colon Cancer Test Kit, the breast and prostate cancer tests under development and future tests for other cancer types. ``The significance of this patent is that it extends protection for the clinical use of fluid-based nuclear matrix proteins for the detection and management of cancer patients until 2011,' said David L. Corbet, President and Chief Operating Officer of Matritech. ``This issuance is the twelfth U.S. patent Matritech has secured covering nuclear matrix protein technology, and strengthens our patent position in all NMPs for the detection and management of cancer. Matritech has additional applications pending with the U.S. Patent and Trademark Office for other NMP inventions.' Matritech's NMP core technology correlates levels of NMPs in body fluids to the presence of cancer. Multiple published clinical studies have validated this ability of NMPs to detect early-stage cancerous abnormalities. Matritech has a deep pipeline of NMP-based products in pre-clinical and clinical development for the detection of major cancers including bladder, cervical, colon, breast and prostate cancers. The NMP22 Test Kit is cleared for marketing in the United States for the management of patients with transitional cell carcinoma of the urinary tract. It is also sold in Europe and Japan, where it is the only approved kit for bladder cancer screening. Matritech, Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein technology, discovered at the Massachusetts Institute of Technology and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast and prostate cancers. Statement Under the Private Securities Litigation Reform Act Any forward-looking statements related to the Company's expectations regarding the Company's existing and future projects are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include, but are not limited to, risks related to the Company's reliance on distribution partners, limited capital resources, unforeseen delays in product development or denials of FDA and other regulatory approvals, future product demand and pricing, competitive products and technical developments and general business and economic conditions. There can be no assurance that the Company's expectation for its products will be achieved. SOURCE: Matritech, Inc.